Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 109, showing 5 Applications out of 543 total, starting on record 31, ending on 35

# Protocol No Study Title Investigator(s) & Site(s)

31.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View

32.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
View

33.

ECCT/21/06/13   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,   and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine   From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults   in Sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
3. Aga khan University Hospital (Nairobi City county)
 
View

34.

ECCT/25/08/03   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human   Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
3. KEMRI-WRP (Kericho county)
4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county)
 
View

35.

ECCT/23/09/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Doreen Terry Karimi
Site(s) in Kenya
Gertrudes Childrens Hospital
 
View